Astek Diagnostics, founded with a mission to revolutionize the treatment of bacterial infections, focuses on developing rapid diagnostic tools for healthcare providers. Their core product, Eugris, is a platform designed to guide physicians in prescribing appropriate antibiotics for patients with bacterial sepsis within one hour by detecting the oxygen consumption of bacteria. This innovative approach aims to improve patient outcomes and combat antibiotic resistance. Astek Diagnostics primarily targets the healthcare market, particularly hospitals and clinics dealing with infectious diseases.

Notable figures affiliated with Astek Diagnostics include experts in microbiology and clinical diagnostics. The company has garnered attention from investors interested in healthcare innovation. Key achievements include the development and implementation of the JIDDU system, which provides one-hour UTI detection and antibiotic sensitivity indication. Astek Diagnostics has made a significant impact by enhancing the precision and speed of antibiotic sensitivity testing, ultimately contributing to better patient care and the fight against antibiotic resistance.